Graft-versus-host disease (GVHD) an evidence-based management guidelines

Turkish Journal of Haematology

Volumn 20, Issue 3, 2003, Pages 123-142

  Akpek, Görgün ^a  

^a UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BUSULFAN; CARBAMAZEPINE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN A; DEXAMETHASONE; FLUDARABINE; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; LAXATIVE; LEVOFLOXACIN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NARCOTIC AGENT; PENICILLIN V POTASSIUM; PHENOBARBITAL; PHENYTOIN; PREDNISONE; RETINOID; RIFAMPICIN; STEROID; SULFADIAZINE SILVER; TACROLIMUS; THALIDOMIDE; TRIAMCINOLONE; UNINDEXED DRUG; VORICONAZOLE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; CHOLESTASIS; CHRONIC DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; CORTICOTROPIN TEST; DIAGNOSTIC VALUE; DIARRHEA; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG INHIBITION; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; DRUG TOXICITY; DRUG WITHDRAWAL; GASTROINTESTINAL DISEASE; GRAFT VERSUS HOST REACTION; HISTOPATHOLOGY; HUMAN; INCIDENCE; INFECTION; JOINT CONTRACTURE; LIVER DISEASE; LYMPH NODE IRRADIATION; MALIGNANT NEOPLASTIC DISEASE; MUSCLE CRAMP; NAUSEA; NEPHROTOXICITY; NEURITIS; NEUROLOGIC DISEASE; NEUTROPENIA; OSTEOPOROSIS; PRACTICE GUIDELINE; PROPHYLAXIS; PUVA; RASH; REVIEW; SALVAGE THERAPY; SEDATION; SEIZURE; SIDE EFFECT; SJOEGREN SYNDROME; SKIN BIOPSY; SKIN CARE; STEM CELL TRANSPLANTATION; SYMPTOMATOLOGY; ULTRAVIOLET A RADIATION; WASTING SYNDROME; WHOLE BODY RADIATION;

EID: 0141429086     PISSN: 13007777     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Sale GE, Lerner KG, Barker EA, Shulman HM, Thomas ED. The skin biopsy in the diagnosis of acute GVHD in man. Am J Pathology 1977;89:621-35.
2. Sale GE, Shulman HM, Hackman RC. Pathology of hematopoietic cell transplantation. In: Thomas ED, Blume KG, Forman SJ (eds). Hematopoietic Cell Transplantation. Massachusetts: Blackwell Science, 1999:248-63.
3. Lerner KG, Kao GF, Storb R, et al. Histopathology of graft-versus-host reaction (GVHR) in human recipients of marrow from HLA-matched sibling donors. Transplant Proc 1974;6:389-93.
4. Spencer GD, Hackman RC, McDonald GB, et al. A prospective study of unexplained nausea and vomiting after marrow transplantation. Transplantation 1986;42:602-7.
5. Shulman HM, Sharma P, Amos D, Fenster LF, McDonald GB. A coded histological study of hepatic graft-versus-host disease after human transplantation. Hepatology 1988;8:463-70.
6. Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplantation for leukemia. N Engl J Med 1986;314:729-35.
7. Storb R, Deeg HJ, Pepe M, et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of acute graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: Long-term follow-up of a controlled trial. Blood 1989;73:1729-34.
8. Nash RA, Pepe MS, Storb R, et al. Acute graft-versus-host disease: Analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood 1992;80:1838-45.
9. Vogelsang GB. Cyclosporine administration guidelines. Johns Hopkins University BMT Clinical Practice and Procedures Manual 2001.
10. Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D, Fay JW, Nademanee A, Antin JH, Christiansen NP, Van Der Jagt R, Herzig RH, Litzow MR, Wolff SN, Longo WL, Petersen FB, Karanes C, Avalos B, Storb R, Buell DN, Maher RM, Fitzsimmons WE, Wingard JR. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998;92:2303-14.
11. Bornhauser M, Thiede C, Schuler U, Platzbecker U, Freiberg-Richter J, Helwig A, Plettig R, Rollig C, Naumann R, Kroschinsky F, Neubauer A, Ehninger G. Dose-reduced conditioning for allogeneic blood stem cell transplantation: Durable engraftment without antithymocyte globulin. Bone Marrow Transplant 2000;26:119-25.
12. Prezpiorka D, Cleary K. Therapy of acute graft-versus-host disease. In: Ball ED, Lister J, Law P (eds). Hematopoietic Stem Cell Therapy, Philadelphia PA: Churchill Livingstone, 2000:531-40.
13. Tutchka PJ, Farmer E, Beschorner WE, et al. Therapy of acute graft-versus-host disease (GVHD)-Baltimore experience. Exp Hematol 1981;9:26.
14. Van Lint MT, Uderzo C, Locasciulli A, et al. Early treatment of acute graft-versus-host disease with high or low-dose 6-methylprednisolone: A multicenter randomized trial from the Italian group for bone marrow transplantation. Blood 1998;92:2288-93.
15. Kendra J, Barret AJ, Lucas C, et al. Response of graft-versus-host disease to high doses of methylprednisolone. Clin Lab Haematol 1981;3:19-26.
16. Kanojia MD, Anagnostou AA, Zander AR, et al. High-dose methylprednisolone treatment of acute graft-versus-host disease after bone marrow transplantation in adults. Transplantation 1984;37:246-9.
17. Deeg HJ, Hanslee-Downee PJ. Management of acute GVHD. Bone Marrow Transplant 1990;6:1-8.
18. Hings IM, Severson R, Filipovich AH, et al. Treatment of moderate and severe acute GVHD after allogeneic bone marrow transplantation. Transplantation 1994;58:437-42.
19. Ely P, Dunitz J, Rogosheke J, et al. Use of a somatostatin analogue, octreotideacetate, in the management of acute gastrointestinal graft-versus-host disease. Am J Med 1991;90:707-10.
20. ER Farmer. The histopathology of graft-versus-host disease. Adv Dermatol 1986;1:173-88.
21. Lee SJ, Klein JP, Barrett AJ, et al. Severity of chronic graft-versus-host disease: Association with treatment-related mortality and relapse. Blood 2002;100:406-14.
22. Sullivan KM, Agura E, Anasetti C, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991;28:250-9.
23. Storek J, Witherspoon RP, Webb D, Storb R. Lack of B cells precursors in marrow transplant recipients with chronic graft-versus-host disease. Am J Hematol 1996;52:82-9.
24. Maury S, Mary JY, Rabian C, et al. Prolonged immune deficiency following allogeneic stem cell transplantation: Risk factors and complications in adult patients. Br J Haematol 2001;115:630-41.
25. Atkinson K, Farewell V, Storb R, et al. Analysis of the infections after human bone marrow transplantation: Role of genotypic nonidentity between marrow donor and recipient and of nonspecific suppressor cells in patients with chronic graft-versus-host disease. Blood 1982;60:714-20.
26. Lapp WS, Ghayur T, Mendes M, et al. The functional and histological basis for graft-versus-host-induced immunosuppression. Immunol Rev 1985;88:107-33.
27. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, Hackman R, Tsoi MS, Storb R, Thomas ED. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980;69:204-17.
28. Atkinson K, Horowitz MM, Gale RP, et al. For the Advisory Committee of the International Bone Marrow Transplant Registry. Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease. Bone Marrow Transplant 1989;4:247-54.
29. Lee SJ, Vogelsang G, Gilman A, et al. A survey of diagnosis, management, and grading of chronic GVHD. Biol Blood Marrow Transplant 2002;8:32-9.
30. Akpek G, Zahurak ML, Piantadosi S, Margolis J, Doherty J, Davidson R, Vogelsang GB. Development of a prognostic model for grading chronic graft-versus-host disease. Blood 2001;97:1219-26.
31. Akpek G. Clinical grading in chronic graft-versus-host disease: Is it time for change? Leuk Lymphoma 2002;43:1211-20.
32. Akpek G, Lee SJ, Flowers ME, Pavletic SZ, Arora M, Lee S, Piantadosi S, Guthrie KA, Lynch JC, Takatu A, Horowitz MM, Antin JH, Weisdorf DJ, Martin PJ, Vogelsang GB. Performance of a new clinical grading system for chronic graft-versus-host disease: A Multi-Center Study. Blood 2003, in press.
33. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75:555-62.
34. Kurtzberg J, Laughlin M, Graham ML, et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med 1996;335:157-66.
35. Gluckman E, Rocha V, Boyer-Chammard A, et al. Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N Engl J Med 1997;337:373-81.
36. Lonnqvist B, Aschan J, Ljungman P, Ringden O. Long term cyclosporine therapy may decrease then risk of chronic graft-versus-host disease. Br J Haematol 1990;74:547-8.
37. Kansu E, Gooley T, Flowers ME, Anasetti C, Deeg HJ, Nash RA, Sanders JE, Witherspoon RP, Appelbaum FR, Storb R, Martin PJ. Administration of cyclosporine for 24 months compared with 6 months for prevention of chronic graft-versus-host disease: A prospective randomized clinical trial. Blood 2001;98:3868-70.
38. Nash RA, Pineiro LA, Storb R, et al. FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors. Blood 1996;88:3634-41.
39. Przepiorka D, Anderlini P, Saliba R, Cleary K, Mehra R, Khouri I, Huh YO, Giralt S, Braunschweig I, Van Besien K, Champlin R. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 2001;98:1695-700.
40. Ogawa H, Soma T, Hosen N, Tatekawa T, et al. Combination of tacrolimus, methotrexate, and methylprednisolone prevents acute but not chronic graft-versus-host disease in unrelated bone marrow transplantation. Transplantation 2002;74:236-43.
41. Wingard J, Vogelsang GB, Deeg HJ. ASH Hematology Education Book, 2002.
42. Vogelsang GB. How I treat chronic graft-versus-host disease. Blood 2001;97:1196-201.
43. Wingard JR, Piantadosi S, Vogelsang GB, et al. Predictors of death from chronic graft-versus-host disease after bone marrow transplantation. Blood 1989;74:1428-35.
44. Flowers MED. Traditional treatment of chronic graft-versus-host disease. Blood and Marrow Transplantation Reviews 2002;12:5-8.
45. Koc S, Leisenring W, Flowers ME, Anasetti C, Deeg HJ, Nash RA, Sanders JE, Witherspoon RP, Storb R, Appelbaum FR, Martin PJ. Therapy for chronic graft-versus-host disease: A randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood 2002;100:48-51.
46. Parker PM, Chao N, Nademanee A, et al. Thalidomide as salvage therapy for chronic graft-versus-host disease. Blood 1995;86:3604-9.
47. Browne PV, Weisdorf DJ, DeFor T, Miller WJ, Davies SM, Filipovich A, McGlave PB, Ramsay NK, Wagner J, Enright H. Response to thalidomide therapy in refractory chronic graft-versus-host disease. Bone Marrow Transplant 2000;26:865-9.
48. Vogelsang GB, Farmer ER, Hess AD, et al. Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med 1992;326:1055-8.
49. Sullivan KM, Mori M, Sanders J, et al. Late complications of allogeneic and autologous marrow transplantation. Bone Marrow Transplant 1992;10:127-134.
50. Akpek G, Lee SM, Anders V, Vogelsang GB. A high-dose pulse steroid regimen for controlling active chronic graft-versus-host disease. Biol Blood Marrow Transplant 2001;7:495-502.
51. Mookerjee B, Altomonte V, Vogelsang G. Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus. Bone Marrow Transplant 1999;24:517-20.
52. Carnevale-Schianca F, Martin P, Sullivan K, Flowers M, Gooley T, Anasetti C, Deeg HJ, Furlong T, McSweeney P, Storb R, Nash RA. Changing from cyclosporine to tacrolimus as salvage therapy for chronic graft-versus-host disease. Biol Blood Marrow Transplant 2000;6:613-20.
53. Koc S, Leisenring W, Flowers ME, Anasetti C, Deeg HJ, Nash RA, Sanders JE, Witherspoon RP, Appelbaum FR, Storb R, Martin PJ. Thalidomide for treatment of patients with chronic graft-versus-host disease. Blood 2000;96:3995-6.
54. Vogelsang GB, Wolf D, Altomonte V, et al. Treatment of chronic graft-versus-host disease with ultraviolet radiation and psorelen (PUVA). Bone Marrow Transplant 1996;17:1061-7.
55. Greinix HT, Volc-Platzer B, Rabitsch W, Gmeinhart B, Guevara-Pineda C, Kalhs P, Krutmann J, Honigsmann H, Ciovica M, Knobler RM. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic GVHD. Blood 1998;92:3098-104.
56. Child FJ, Ratnavel R, Watkins P, Samson D, Apperley J, Ball J, Taylor P, Russell-Jones R. Extracorporeal photopheresis (ECP) in the treatment of chronic graft-versus-host disease (GVHD). Bone Marrow Transplant 1999;23:881-7.
57. Foss FM, Görgün G, Miller KB. Extracorporeal photopheresis in chronic graft-versus-host disease. Bone Marrow Transplant 2002;29:719-25.
58. Owsianowski M, Gollinck H, Siegert W, et al. Successful treatment of chronic graft-versus-host disease with extracorporeal photopheresis. Bone Marrow Transplant 1994;14:845-8.
59. Rosetti F, Zulian F, Dall'Amico R, et al. Extracorporeal photochemotherapy as single therapy for extensive, cutaneous, chronic graft-versus-host disease. Transplantation 1995;59:149-51.
60. Alcindor T, Görgün G, Miller KB, Roberts TF, Sprague K, Schenkein DP, Foss FM. Immunomodulatory effects of extracorporeal photochemotherapy in patients with extensive chronic graft-versus-host disease. Blood 2001;98:1622-5.
61. Guardiola P, Fernandez G, Girinski T, Socie G, Ribaud P, Esperou H, Gluckman E, Devergie A. Low-dose thoracoabdominal irradiation for the treatment of refractory chronic GVHD (abstract). Blood 2002;100(Suppl I):3341a.
62. Marcellus DC, Altomonte VL, Farmer ER, Horn TD, Freemer CS, Grant J, Vogelsang GB. Etretinate therapy for refractory sclerodermatous chronic graft-versus-host disease. Blood 1999;93:66-70.
63. Gilman AL, Chan KW, Mogul A, Morris C, Goldman FD, Boyer M, Cirenza E, Mazumder A, Gehan E, Cahill R, Frankel S, Schultz K. Hydroxychloroquine for the treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2000;6:327-34.
64. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 2000;6:659-713,715,717-27.